拉丁美洲多发性硬化症和视神经脊髓炎谱系疾病患者中的 COVID-19：拉丁美洲多发性硬化症和视神经脊髓炎谱系疾病患者中的 COVID-19。
COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.
机构信息
Centro Universitario de Esclerosis Múltiple. Hospital Ramos Mejía, Buenos Aires, Argentina; Servicio de Neurología, Hospital Universitario Sanatorio Guemes, Argentina.
Servicio de Neurología, Hospital Universitario Sanatorio Guemes, Argentina.
出版信息
Mult Scler Relat Disord. 2021 Jun;51:102886. doi: 10.1016/j.msard.2021.102886. Epub 2021 Mar 7.
BACKGROUND
There is no data regarding COVID-19 in Multiple Sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients in Latin America.
OBJECTIVE
The objective of this study was to describe the clinical characteristics and outcomes of patients included in RELACOEM, a LATAM registry of MS and NMOSD patients infected with COVID-19.
METHODS
RELACOEM is a longitudinal, strictly observational registry of MS and NMOSD patients who suffer COVID-19 and Dengue in LATAM. Inclusion criteria to the registry were either: (1) a biologically confirmed COVID-19 diagnosis based on a positive result of a COVID-19 polymerase chain reaction (PCR) test on a nasopharyngeal swab; or (2) COVID-19-typical symptoms (triad of cough, fever, and asthenia) in an epidemic zone of COVID-19. Descriptive statistics were performed on demographic and clinical variables. The cohort was later stratified for MS and NMOSD and univariate and multivariate logistic regression analysis was performed to identify variables associated with hospitalizations/intensive critical units (ICU) admission.
RESULTS
145 patients were included in the registry from 15 countries and 51 treating physicians. A total of 129 (89%) were MS patients and 16 (11%) NMOSD. 81.4% patients had confirmed COVID-19 and 18.6% were suspected cases. 23 (15.8%) patients were hospitalized, 9 (6.2%) required ICU and 5 (3.4 %) died due to COVID-19. In MS patients, greater age (OR 1.17, 95% CI 1.05 - 1.25) and disease duration (OR 1.39, 95%CI 1.14-1.69) were associated with hospitalization/ICU. In NMOSD patients, a greater age (54.3 vs. 36 years, p=<0.001), increased EDSS (5.5 vs 2.9, p=0.0012) and disease duration (18.5 vs. 10.3 years, p=0.001) were significantly associated with hospitalization/ICU.
CONCLUSION
we found that in MS patients, age and disease duration was associated with hospitalization and ICU admission requirement, while age, disease duration and EDSS was associated in NMOSD.
背景
拉丁美洲尚缺乏关于 COVID-19 感染多发性硬化症（MS）和视神经脊髓炎谱系疾病（NMOSD）患者的相关数据。
目的
本研究旨在描述 RELACOEM 登记处中 COVID-19 感染 MS 和 NMOSD 患者的临床特征和结局，该登记处为拉丁美洲 MS 和 NMOSD 患者 COVID-19 和登革热的纵向、严格观察性登记处。登记处的纳入标准为：（1）鼻咽拭子 COVID-19 聚合酶链反应（PCR）检测阳性的生物确诊 COVID-19 诊断；或（2）COVID-19 流行区出现 COVID-19 典型症状（咳嗽、发热和乏力三联征）。对人口统计学和临床变量进行描述性统计。随后，根据 MS 和 NMOSD 对队列进行分层，并进行单变量和多变量逻辑回归分析，以确定与住院/重症监护单位（ICU）入院相关的变量。
结果
该登记处共纳入来自 15 个国家的 15 名医生治疗的 145 名患者。共有 129 名（89%）患者为 MS 患者，16 名（11%）患者为 NMOSD。81.4%的患者确诊 COVID-19，18.6%的患者疑似 COVID-19。23 名（15.8%）患者住院，9 名（6.2%）需要 ICU 治疗，5 名（3.4%）因 COVID-19 死亡。在 MS 患者中，年龄较大（比值比 [OR] 1.17，95%置信区间 [CI] 1.05-1.25）和疾病持续时间较长（OR 1.39，95%CI 1.14-1.69）与住院/ICU 相关。在 NMOSD 患者中，年龄较大（54.3 岁 vs. 36 岁，p<0.001）、EDSS 较高（5.5 分 vs. 2.9 分，p=0.0012）和疾病持续时间较长（18.5 年 vs. 10.3 年，p=0.001）与住院/ICU 相关。
结论
我们发现，在 MS 患者中，年龄和疾病持续时间与住院和 ICU 入院需求相关，而 NMOSD 中年龄、疾病持续时间和 EDSS 相关。
Zotero 插件